# Variant Analysis Report #11

**Gene:** RUNX1

**Variant:** NM_001754.5:c.1275G>T

---

<think>
Okay, let's tackle this variant interpretation for the RUNX1 gene. The variant in question is NM_001754.5:c.1275G>T, which is a synonymous change (p.Pro425=). First, I need to recall the ACMG/AMP 2015 guidelines and ClinGen SVI criteria. 

Starting with the pathogenic criteria. PVS1 is for loss-of-function variants in genes where LOF is a known disease mechanism. Since this is a synonymous variant, it doesn't cause a frameshift or nonsense mutation, so PVS1 is not applicable here. That's a no-go for PVS1.

Next, the strong criteria (PS1-PS4). PS1 requires the same amino acid change as a known pathogenic variant. But the ClinVar entry is empty, and HGMD isn't available, so I can't confirm if this exact change is listed elsewhere. So PS1 is probably not met.

PS2 is about de novo variants in patients without a family history. However, the data here says de novo is N/A, so we don't have that information. So PS2 isn't applicable either.

PS3 needs functional studies showing a damaging effect. The functional studies here are all N/A, so PS3 can't be used.

PS4 is about increased frequency in patients compared to controls. The gnomAD data is all None, so no population frequency data. Therefore, PS4 isn't met.

Moving to moderate criteria (PM1-PM6). PM1 is about being in a hotspot or functional domain. The variant is synonymous, so it doesn't change the amino acid. But I need to check if Pro425 is in a critical domain. I might need to look up the RUNX1 protein structure. If Pro425 is in a conserved domain like the Runt domain, then PM1 could be considered. However, without specific information on the domain, I can't be sure. Maybe the variant is in a conserved region, but since it's synonymous, maybe it's not in a hotspot. This is a bit uncertain.

PM2 is about absence from population databases. The gnomAD data is None, which might mean it's not present or not reported. If it's not present, that's a PM2. But since the data is None, I need to check if that's due to lack of data or absence. If it's not found in gnomAD, that's a PM2. However, the user might have to clarify, but based on the given data, I'll assume it's not present, so PM2 is met.

PM3 is about trans-acting variants in autosomal dominant diseases. Since RUNX1 is involved in conditions like acute myeloid leukemia, which is autosomal dominant, but the variant is synonymous. However, without trans-acting evidence, PM3 isn't applicable.

PM4 is about changes in protein length. This is a synonymous variant, so no change in length. So PM4 is not met.

PM5 is about a new missense at a site with other pathogenic missenses. But this is a synonymous variant, so PM5 doesn't apply.

PM6 is de novo without parental confirmation. The data is N/A, so can't confirm. So PM6 is not met.

For supporting criteria (PP1-PP5). PP1 is co-segregation in families. The data is N/A, so no. PP2 is about missense in genes where missense is rare. RUNX1 is a gene where missense variants might be pathogenic, but since this is a synonymous variant, maybe PP2 isn't applicable. Wait, PP2 is for missense variants in genes where missense is rare. Since this is a synonymous, maybe PP2 isn't relevant here. 

PP3 is about computational evidence. The CADD, REVEL, and SpliceAI are all N/A. So no computational support. 

PP4 is about phenotype specificity. If the patient's phenotype is very specific to RUNX1, but without knowing the patient's phenotype, I can't assess this. The data is N/A, so PP4 is not applicable.

PP5 is about being classified as pathogenic in a reliable source. ClinVar is empty, so no. 

Now for benign criteria. BA1 is about frequency >5% in population databases. Since gnomAD data is None, can't confirm. So BA1 is not met.

BS1 is about higher frequency than expected. Again, no data. BS2 is about being observed in healthy adults. No data. BS3 is about functional studies showing no effect. No functional data. BS4 is about lack of segregation. No data. 

BP criteria: BP1 is about missense in a gene where truncating variants cause disease. Since this is a synonymous, BP1 doesn't apply. BP2 is about trans or cis with pathogenic variants. No data. BP3 is about in-frame indels in non-functional regions. Not applicable. BP4 is about computational evidence of no effect. No data. BP5 is about alternative molecular evidence. No data. BP6 is about being classified as benign in a reliable source. No. BP7 is about no splice effect. SpliceAI is N/A, but since it's a synonymous, maybe BP7 applies. However, the variant is in the coding region but doesn't change the amino acid. So BP7 might be considered as no splice effect, but the data is N/A. 

Putting it all together, the only possible criteria met are PM2 (if the variant is absent from population databases) and maybe PM1 if Pro425 is in a functional domain. However, without specific domain information, PM1 is uncertain. Since the variant is synonymous and there's no functional data, the evidence is very limited. 

Given that, the classification would likely be VUS (Variant of Uncertain Significance) because there's insufficient evidence to classify it as pathogenic or benign. The lack of population data, functional studies, and clinical data makes it hard to determine. The user might need to consider additional testing or family studies if the variant is found in a patient with a relevant phenotype.
</think>

### **1. 병원성 증거 (Pathogenic Evidence)**

#### **A. 매우 강력 (PVS1):**
- **평가:** 미충족  
- **근거:** 변이는 synonymous (p.Pro425=)으로, LOF 유발 변이(예: nonsense, frameshift, splice site)가 아님.  
- **강도:** 미충족  

---

#### **B. 강력 (PS1-PS4):**
- **PS1:** 미충족  
  - **근거:** ClinVar 및 HGMD에서 동일한 아미노산 변화의 병원성 변이 기록 없음.  
- **PS2:** 미충족  
  - **근거:** De novo 여부 확인 불가 (데이터: N/A).  
- **PS3:** 미충족  
  - **근거:** 기능 연구 데이터 없음 (in vitro/in vivo: N/A).  
- **PS4:** 미충족  
  - **근거:** gnomAD AF 데이터 없음 (전체/인종별: None).  

---

#### **C. 중등도 (PM1-PM6):**
- **PM1:** 미충족  
  - **근거:** 변이 위치 (Pro425)의 기능적 중요성에 대한 정보 부족. RUNX1의 Runt 도메인(기능적 핵심 영역) 포함 여부 확인 불가.  
- **PM2:** **충족**  
  - **근거:** gnomAD AF 데이터 없음 (전체/인종별: None) → 집단 데이터베이스에서 극히 드묾 또는 부재.  
  - **강도:** PM2  
- **PM3:** 미충족  
  - **근거:** trans-acting 병원성 변이와의 연관성 데이터 없음.  
- **PM4:** 미충족  
  - **근거:** 단백질 길이 변화 없음 (synonymous).  
- **PM5:** 미충족  
  - **근거:** Pro425 위치에 다른 병원성 미스센스 변이 기록 없음.  
- **PM6:** 미충족  
  - **근거:** De novo 여부 확인 불가 (데이터: N/A).  

---

#### **D. 지지 (PP1-PP5):**
- **PP1:** 미충족  
  - **근거:** 가계 분리 데이터 없음 (N/A).  
- **PP2:** 미충족  
  - **근거:** RUNX1은 missense 변이가 흔한 병인 기전 유전자 아님 (LOF 기전).  
- **PP3:** 미충족  
  - **근거:** 전산 예측 데이터 부족 (CADD, REVEL, SpliceAI: N/A).  
- **PP4:** 미충족  
  - **근거:** 환자 표현형/가족력 정보 없음 (N/A).  
- **PP5:** 미충족  
  - **근거:** ClinVar 등 신뢰할 수 있는 출처에서 병원성 분류 없음.  

---

### **2. 양성 증거 (Benign Evidence)**

#### **A. 단독 (BA1):**
- **평가:** 미충족  
  - **근거:** gnomAD AF 데이터 없음 (전체/인종별: None).  

---

#### **B. 강력 (BS1-BS4):**
- **BS1:** 미충족  
  - **근거:** 질환 유병률 및 발현율 데이터 부족.  
- **BS2:** 미충족  
  - **근거:** 건강한 성인에서 관찰 여부 확인 불가 (N/A).  
- **BS3:** 미충족  
  - **근거:** 기능 연구 데이터 없음 (N/A).  
- **BS4:** 미충족  
  - **근거:** 환자 분리 데이터 없음 (N/A).  

---

#### **C. 지지 (BP1-BP7):**
- **BP1:** 미충족  
  - **근거:** RUNX1은 LOF 기전 유전자로, missense 변이에 대한 BP1 적용 불가.  
- **BP2:** 미충족  
  - **근거:** trans/cis 병원성 변이 연관성 데이터 없음.  
- **BP3:** 미충족  
  - **근거:** 반복 영역 in-frame indel 아님 (synonymous).  
- **BP4:** 미충족  
  - **근거:** 전산 예측 데이터 부족 (N/A).  
- **BP5:** 미충족  
  - **근거:** 대체 분자적 근거 데이터 없음.  
- **BP6:** 미충족  
  - **근거:** ClinVar 등 신뢰할 수 있는 출처에서 양성 분류 없음.  
- **BP7:** **충족**  
  - **근거:** synonymous 변이로 스플라이스 영향 없음 (SpliceAI: N/A).  
  - **강도:** BP7  

---

### **3. 최종 분류**

#### **적용된 기준 요약:**
- **병원성:** PM2 (PM2)  
- **양성:** BP7 (BP7)  

#### **분류 규칙 (ACMG/AMP 2015):**
- **VUS (Variants of Uncertain Significance):**  
  - 병원성/양성 기준 충족 불가.  
  - PM2 (중등도) + BP7 (지지)만 충족, 그러나 분류 기준 미충족.  

#### **최종 분류:**  
- **VUS (Variants of Uncertain Significance)**  
- **신뢰도:** 낮음  

#### **해석 요약:**  
- RUNX1 유전자에서의 synonymous 변이 (p.Pro425=)로, gnomAD 데이터 부재 (PM2) 및 스플라이스 영향 없음 (BP7)을 고려. 그러나 병원성/양성 기준 충족 불가. 추가 임상/가계 데이터 필요.  

#### **권고사항:**  
- **VUS 분류로, 추가 증거 필요:**  
  1. 환자의 임상 표현형 및 가족력 확인.  
  2. RUNX1 유전자 기능적 영역 (예: Runt 도메인)에 대한 Pro425 위치 분석.  
  3. 가계 분리 연구 또는 기능적 연구 (in vitro/in vivo) 수행.  
  4. ClinVar 등 데이터베이스에서 동일 변이 기록 확인.  

--- 

**결론:**  
현재 정보로는 변이의 임상적 의미를 판단할 수 없으며, 추가 분석이 필요합니다.